imipramine has been researched along with cyclosporine in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (12.50) | 18.2507 |
| 2000's | 8 (33.33) | 29.6817 |
| 2010's | 13 (54.17) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bacsó, Z; Cianfriglia, M; Fenyvesi, F; Goda, K; Kappelmayer, J; Lustyik, G; Nagy, H; Szabó, G; Szilasi, M | 1 |
| Chang, TK; Ensom, MH; Kiang, TK | 1 |
| Li, Y; Li, YH; Wang, YH; Yang, L; Yang, SL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Erdmann, F; Fischer, G; Harris, R; Hopkins, S; Huang, Z; Murray, MG; Ribeill, Y; Scorneaux, B; Smitley, C; Wring, S | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Basso, AM; Depiante-Depaoli, M; Molina, VA | 1 |
| Caraco, Y; Putterman, C; Zylber-Katz, E | 1 |
| Chou, JW; Pritchard, PH; Ramaswamy, M; Subramanian, R; Wasan, KM | 1 |
| Fujisaki, C; Hirokawa, K; Kitagawa, M; Kuroda, Y; Seidler, H; Utsuyama, M; Watanabe, A; Watanabe, S | 1 |
| Bachran, C; Fuchs, H; Melzig, MF; Weng, A | 1 |
| Clarke, G; Cryan, JF; Dinan, TG; Fitzgerald, P; Griffin, BT; O'Brien, FE | 1 |
| Honda, H; Ito, Y; Kawamoto, T; Morita, O | 1 |
2 review(s) available for imipramine and cyclosporine
| Article | Year |
|---|---|
UDP-glucuronosyltransferases and clinical drug-drug interactions.
Topics: Clinical Trials as Topic; Drug Interactions; Enzyme Activation; Enzyme Induction; Glucuronides; Glucuronosyltransferase; Humans; Pharmaceutical Preparations; Pharmacogenetics; Polymorphism, Genetic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
22 other study(ies) available for imipramine and cyclosporine
| Article | Year |
|---|---|
Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies.
Topics: Adenosine Triphosphatases; Animals; Anti-Bacterial Agents; Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding, Competitive; Calcium Channel Blockers; Cyclosporine; Detergents; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Fluoresceins; Humans; Ivermectin; Mice; NIH 3T3 Cells; Substrate Specificity | 2004 |
Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.
Topics: Computational Biology; Cyclohexanols; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Molecular Structure; Principal Component Analysis; Pyrrolizidine Alkaloids; Quantitative Structure-Activity Relationship; Reproducibility of Results; Substrate Specificity; Venlafaxine Hydrochloride | 2005 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
Topics: Animals; Antiviral Agents; Cell Line; Cells, Cultured; Cyclophilin A; Cyclosporins; Dogs; Dose-Response Relationship, Drug; Enzyme Activation; Haplorhini; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Immunosuppressive Agents; Interleukin-2; Jurkat Cells; Leukocytes, Mononuclear; Mice; Molecular Structure; Rats; RNA, Viral; Virus Replication | 2010 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Chronic variable stress facilitates tumoral growth: reversal by imipramine administration.
Topics: Animals; Cyclosporine; Depression; Disease Models, Animal; Imipramine; Immune Tolerance; Immunity; Male; Neoplasm Transplantation; Rats; Rats, Inbred Strains; Sarcoma, Experimental; Stress, Physiological | 1992 |
Multiple drug overdose in a kidney transplant patient.
Topics: Chromatography, Thin Layer; Cyclosporine; Depression; Drug Overdose; Half-Life; Humans; Imipramine; Kidney Transplantation; Male; Middle Aged; Radioimmunoassay; Suicide, Attempted | 1994 |
Cyclosporine transfer from low- and high-density lipoproteins is partially influenced by lipid transfer protein I triglyceride transfer activity.
Topics: Adrenergic Uptake Inhibitors; Biological Transport; Carrier Proteins; Cyclosporine; Humans; Imipramine; Immunosuppressive Agents; Lipoproteins, HDL; Lipoproteins, LDL; Triglycerides; Tritium | 1999 |
An immnosuppressive drug, cyclosporine-A acts like anti-depressant for rats under unpredictable chronic stress.
Topics: Adrenal Glands; Analysis of Variance; Animals; Antidepressive Agents; Behavior; Biogenic Monoamines; Chronic Disease; Cyclosporine; Dose-Response Relationship, Drug; Frontal Lobe; Imipramine; Immunosuppressive Agents; Injections, Intraperitoneal; Male; Motor Activity; Organ Size; Rats; Rats, Inbred F344; Reaction Time; Stress, Physiological | 2003 |
Soapwort saponins trigger clathrin-mediated endocytosis of saporin, a type I ribosome-inactivating protein.
Topics: Cell Membrane; Cell Membrane Permeability; Cell Survival; Cells, Cultured; Chlorpromazine; Clathrin; Cyclosporine; Dose-Response Relationship, Drug; Endocytosis; Endosomes; Filipin; Humans; Imipramine; Macrolides; Microscopy, Fluorescence; Microtubules; Nocodazole; Okadaic Acid; Recombinant Proteins; Ribosome Inactivating Proteins, Type 1; Ribosome Inactivating Proteins, Type 2; Ribosomes; Saponins; Saporins; Toxins, Biological | 2008 |
Inhibition of P-glycoprotein enhances transport of imipramine across the blood-brain barrier: microdialysis studies in conscious freely moving rats.
Topics: Animals; Antidepressive Agents, Tricyclic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biotransformation; Blood-Brain Barrier; Cyclosporine; Desipramine; Drug Interactions; Extracellular Fluid; Half-Life; Imipramine; Injections, Intravenous; Male; Metabolic Clearance Rate; Microdialysis; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Tissue Distribution; Verapamil | 2012 |
Mechanism-based risk assessment strategy for drug-induced cholestasis using the transcriptional benchmark dose derived by toxicogenomics.
Topics: Administration, Oral; Animals; Chlorpromazine; Cholestasis; Cholesterol; Cyclosporine; Diclofenac; Dose-Response Relationship, Drug; Flutamide; Gene Expression; Humans; Imipramine; Inflammation; Ketoconazole; Liver; Methyltestosterone; Oxidative Stress; Rats; Risk Assessment; Sulindac; Tamoxifen; Toxicogenetics | 2017 |